| |
| |
| Catalent Expands Comprehensive Inhalation Capabilities: Agrees to Acquire Dry Powder Inhaler Facility from Acorda Therapeutics |
|
|
|
| The acquisition complements Catalent’s status as a premier U.S.-based partner for companies across dry powder inhaled dose forms. Under the terms of the agreement, Catalent will acquire Acorda Therapeutics’ 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, which operates best-in-class spray drying capacity. |
|
| | |
|
|
| |
| |
| |
| Novan Engages Catalent to Develop Intranasal Formulation for COVID-19
Catalent welcomes the announcement by its partner, Novan, for Catalent to support chemistry, manufacturing, and control activities and development of an intranasal formulation of berdazimer sodium for use in the Novan’s coronavirus (COVID-19) program. |
|
|
|
| |
| Catalent is Proud to Support Many High-Profile COVID-19 Programs
Catalent has been awarded more than 60 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. |
|
|
|
| |
| |
| GPEx® Boost Shortlisted for The Medicine Maker’s Innovation Awards
GPEx Boost builds on Catalent’s proprietary GPEx technology with enhanced benefits, including up to four-fold higher titers in difficult-to-express proteins, reduced ammonia build-up to improve cell growth and viability, and fewer process steps. Vote for GPEx Boost. |
|
|
|
| |
| |
| |
| |
| |
| Innovations in Vaccine Technology and Partnerships Covered in Pharma’s Almanac
Recently published in Pharma’s Almanac, experts from Arcturus Therapeutics and Catalent Biologics discuss their partnership to develop and scale a novel mRNA-based COVID-19 vaccine program, including the ways they are collaborating to enable and expedite large-scale manufacturing. |
|
|
|
| |
| |
| Catalent Featured in Wall Street Journal
Bernie Clark, Vice President, Marketing & Strategy, Catalent Biologics, discusses the continued need for more talent to fuel the manufacturing demand of COVID-19 vaccines, therapies and other life-saving medicines. |
|
|
|
| |
| |
| Pharma’s Almanac Risk Mitigation Roundtable
Catalent’s Kay Schmidt, Senior Vice President, Technical Operations, joined industry experts to discuss techniques for risk management and mitigation. |
|
|
|
| |
| Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and Technology Development Programs |
|
|
|
| |
| |
| |
| |
| |
| A Catalyst in Drug Development | | Dejan Lamesic, Ph.D. Product Development Scientific Team Leader, Catalent Schorndorf |
|
|
|
| Dr. Lamesic specializes in the material science of excipients, specifically fillers and polymers for immediate and controlled-release solid dosage forms. His expertise in particle engineering and the compaction process includes tableting and dry granulation. Discover what drives Dejan’s passion for pharmaceutical materials science: read his published works including peer-reviewed articles, and register for his upcoming webinar. |
|
| | |
|
|
| |
| |
| |
| Biologics
Webinar: “Women in Biopharma Awards 2020”- Catalent and Endpoints News highlight the top 20 women in biopharma who have made it to the upper echelons of the drug development business in this on-demand webinar. Article: “Enhancing Regulatory Approval in Bioprocessing” - Published in Genetic Engineering and Biotechnology News, Claudia Berdugo, Ph.D., Director of Process Development, Catalent Biologics, joins other industry experts to discuss the best strategies to gain approval for a bioprocess. Webinar: “How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms” - Recorded at BioEurope, Mario Gargiulo, Catalent’s Region President, Biologics, Europe, joins Dan Stanton, Editor and Founder, Bioprocess Insider, in a fireside chat interview. Article: “Pinpointing Bioprocess Development Success” - In a recent BioPharm International article, Catalent Biologics’ Timothy Morris, Group Leader, Manufacturing Process Development, discusses the ways collaboration, analytics, and high-throughput system integration can increase the chance of success. |
|
| | |
|
|
| |
| |
| |
| |
| We are the Catalyst for your Success. Join Us! |
|
|
|
| Catalent ignites the development of their future leaders by continuously investing in our employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana, Madison, Wisconsin, Winchester, Kentucky, and more.
Visit www.catalent.com/careers for more information. |
|
| | |
|
|
| |
| |
| Every brand has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
| |
